This randomized phase III trial studies a diet and exercise program based on the Diabetes Prevention Program to promote weight loss and improve health in men with low-risk or low-intermediate-risk prostate cancer on active surveillance. A lifestyle intervention that promotes weight loss may influence prostate health. A combined diet and exercise program that is based on the Diabetes Prevention Program may affect markers (or "biomarkers") of prostate cancer progression. Gathering this information may help doctors understand how obesity affects prostate cancer progression and may help lead to a program that can reduce the risk of prostate cancer progression.
PRIMARY OBJECTIVES: I. To test whether the Diabetes Prevention Program (DPP) lifestyle intervention (versus \[vs.\] control) improves serum fasting glucose. II. To test whether the DPP lifestyle intervention (vs. control) improves serum biomarkers of glucose regulation (insulin, C-peptide, insulin-like growth factor-1 \[IGF-1\], IGF binding protein 3 \[IGF-BP3\] and adiponectin). III. To test whether the DPP lifestyle intervention decreases the levels of insulin receptor or insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer (PCa) tissue epithelium on follow-up prostate biopsy. IV. To test whether PCa patients randomized to the DPP lifestyle intervention sustain the lifestyle changes for at least 6 months after the end of the intervention period. SECONDARY OBJECTIVES: I. To evaluate whether the DPP lifestyle intervention improves health-related quality of life. II. To evaluate whether the DPP lifestyle intervention effects on pathologic features of follow-up prostate biopsies. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients meet with a nutritionist 11 times during the first 6 months to receive the structured diet and exercise instruction. Participants complete exercise sessions supervised by an exercise specialist, and will wear a heart rate monitor periodically during the study. ARM II: Patients receive oral and written information based on general U.S. dietary and physical activity guidelines along with a 20-30 minute individual session with a dietitian and a goal of 30 minutes of physical activity 5 days a week. After completion of study, patients are followed up at 3, 6, and 12 months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
117
Undergo DPP lifestyle intervention
Undergo DPP lifestyle intervention
Receive oral and written guidelines and meet with dietician
Correlative studies
Ancillary studies
Ancillary studies
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
Change From Baseline in Fasting Glucose at 6 Months
Mean and standard deviation of change from baseline.
Time frame: Baseline to 6 months
Change From Baseline in Fasting C-peptide, IGF-1, IGF-BP3, and Adiponectin at 6 Months
Mean and standard deviation of change from baseline.
Time frame: Baseline to 6 months
Change in Expression of Insulin Receptor (IR), IGF-1R, and Protein Kinase B (AKT) on Prostate Cancer Epithelial Cells
Mean and standard deviation of change from baseline.
Time frame: Baseline (6 months prior to randomization) to follow-up surveillance biopsy (6 months post-randomization)
Weight at 12 Months
Mean and standard deviation of weight at 12 months
Time frame: 12 months (6 months after active intervention)
Change From Baseline in Fasting Insulin at 6 Months
Mean and standard deviation of change from baseline.
Time frame: Baseline to 6 months
Health Related Quality of Life (HRQOL) at 6 Months
Mean and standard deviation of Quality of Life measures at 6 months.
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.